BioCryst to buy Astria Therapeutics in $700 million deal
14/10/2025 12:16
Oct 14 (Reuters) - BioCryst Pharmaceuticals BCRX.O said on Tuesday it would buy Astria Therapeutics ATXS.O in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026